AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)
AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)

Balance Sheet ACRS Quote Aclaris The

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 10 30 20
ShortTermInvest 75 107 174
Cash 85 137 194
AccountReceivab 0 0 0
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 0 0 0
TotalCurrentAss 87 139 200
PPE 0 1 3
AccumulatedDepr 0 0 0
NetPPE 0 0 2
EquityAndOtherI 7 37 15
Goodwill 0 0 19
IntangibleAsset 0 0 7
OtherLTAssets 0 0 0
TotalNonCurrent 8 38 43
TotalAssets 94 176 244
ShortTermDebt 0 0 0
AccountsPayable 1 3 8
TaxesPayable 0 0 0
AccruedLiabilit 1 2 1
DeferredRevenue 0 0 0
OtherCurrentLia 0 2 4
TotalCurrentLia 2 6 13
Debt 0 0 0
DeferredTaxesLi 0 0 1
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 5
TotalNonCurrent 0 0 5
TotalLiabilitie 2 7 18
CommonStock 0 0 0
AdditionalPaidI 136 261 385
RetainedEarning -43 -91 -159
AccumulatedOthe 0 0 0
TotalStockholde 93 169 225
TotalLiabilitie 94 176 244
Aclaris Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Aclaris Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.